Related Experiment Video
Updated: Jul 2, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.1K
Atypical Presentation of Metastatic Castrate-resistant Prostate Cancer in a Middle Aged African Male with Good
Osayande Evbuomwan1, Walter Endres1, Tebatso Tebeila1
1University of The Free State, Department of Nuclear Medicine, Bloemfontein, South Africa.
Molecular Imaging and Radionuclide Therapy
|February 23, 2024
Summary
This case study highlights an African man with aggressive prostate cancer showing both typical and unusual metastatic patterns. Fluorine 18 PSMA PET/CT imaging revealed the spread, and radioligand therapy proved effective.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Prostate cancer commonly metastasizes to pelvic lymph nodes and bone.
- African men often experience a more aggressive prostate cancer course.
- Atypical metastatic patterns, though rare, can occur.
Purpose of the Study:
- To present a case of metastatic castrate-resistant prostate cancer in an African male.
- To illustrate both typical and atypical metastatic patterns.
- To demonstrate the utility of fluorine 18 prostate-specific membrane antigen positron emission tomography/computed tomography (F-18 PSMA PET/CT) in detecting metastasis.
- To report the patient's response to radioligand therapy.
Main Methods:
- Case report of a 58-year-old African male.
- Diagnostic imaging using F-18 PSMA PET/CT scan.
- Treatment with radioligand therapy.
Main Results:
- The F-18 PSMA PET/CT scan identified both typical (pelvic lymph nodes, bone) and atypical metastatic sites.
- The patient exhibited a positive response to radioligand therapy.
Conclusions:
- Metastatic castrate-resistant prostate cancer in African men can present with atypical patterns.
- F-18 PSMA PET/CT is a valuable tool for comprehensive detection of prostate cancer metastasis.
- Radioligand therapy can be an effective treatment option for metastatic prostate cancer.
